George L Sing Regeneron Pharmaceuticals, Inc. (REGN) insider trading activity

REGN Quotes by TradingView

George L Sing is Director of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 26,272 shares of REGN, which is worth approximately $19.5 Million. The most recent transaction as insider was on Sep 04, 2024, when has been sold 1,200 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 26.3K
4.37% 3M change
0.22% 12M change
Total Value Held $19.5 Million

GEORGE L SING Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 04 2024
SELL
Bona fide gift
-
1,200 Reduced 4.37%
26,272 Common Stock
May 03 2024
SELL
Payment of exercise price or tax liability
$826,598 $942.53 p/Share
877 Reduced 3.09%
27,472 Common Stock
May 03 2024
BUY
Exercise of conversion of derivative security
$826,660 $413.33 p/Share
2,000 Added 6.59%
28,349 Common Stock
Feb 26 2024
SELL
Open market or private sale
$992,500 $992.5 p/Share
1,000 Reduced 3.66%
26,349 Common Stock
Feb 26 2024
BUY
Exercise of conversion of derivative security
$413,330 $413.33 p/Share
1,000 Added 3.59%
26,849 Common Stock
Feb 23 2024
SELL
Open market or private sale
$492,500 $985.0 p/Share
500 Reduced 1.86%
26,349 Common Stock
Feb 23 2024
BUY
Exercise of conversion of derivative security
$206,665 $413.33 p/Share
500 Added 1.83%
26,849 Common Stock
Feb 22 2024
SELL
Open market or private sale
$2,895,000 $965.0 p/Share
3,000 Reduced 10.22%
26,349 Common Stock
Feb 22 2024
BUY
Exercise of conversion of derivative security
$1,239,990 $413.33 p/Share
3,000 Added 9.89%
27,349 Common Stock
Feb 09 2024
SELL
Open market or private sale
$477,500 $955.0 p/Share
500 Reduced 1.86%
26,349 Common Stock
Feb 09 2024
BUY
Exercise of conversion of derivative security
$206,665 $413.33 p/Share
500 Added 1.83%
26,849 Common Stock
Feb 08 2024
SELL
Open market or private sale
$472,500 $945.0 p/Share
500 Reduced 1.86%
26,349 Common Stock
Feb 08 2024
BUY
Exercise of conversion of derivative security
$206,665 $413.33 p/Share
500 Added 1.83%
26,849 Common Stock
Jan 02 2024
BUY
Grant, award, or other acquisition
-
135 Added 0.51%
26,349 Common Stock
Jan 03 2023
BUY
Grant, award, or other acquisition
-
165 Added 0.63%
26,214 Common Stock
Feb 28 2022
SELL
Open market or private sale
$1,231,000 $615.5 p/Share
2,000 Reduced 7.13%
26,049 Common Stock
Feb 25 2022
SELL
Open market or private sale
$1,242,000 $621.0 p/Share
2,000 Reduced 6.66%
28,049 Common Stock
Jan 03 2022
BUY
Grant, award, or other acquisition
-
191 Added 0.63%
30,049 Common Stock
Nov 22 2021
SELL
Open market or private sale
$1,315,000 $657.5 p/Share
2,000 Reduced 6.28%
29,858 Common Stock
Nov 19 2021
SELL
Open market or private sale
$655,000 $655.0 p/Share
1,000 Reduced 3.04%
31,858 Common Stock
Nov 18 2021
SELL
Open market or private sale
$2,600,000 $650.0 p/Share
4,000 Reduced 10.85%
32,858 Common Stock
Nov 16 2021
SELL
Open market or private sale
$3,937,560 $656.26 p/Share
6,000 Reduced 14.0%
36,858 Common Stock
Aug 30 2021
SELL
Open market or private sale
$672,500 $672.5 p/Share
1,000 Reduced 2.28%
42,858 Common Stock
Aug 16 2021
SELL
Open market or private sale
$444,150 $630.0 p/Share
705 Reduced 1.58%
43,858 Common Stock
Aug 13 2021
SELL
Open market or private sale
$310,000 $620.0 p/Share
500 Reduced 1.11%
44,563 Common Stock
GLS

George L Sing

Director
Tarrytown, NY

Track Institutional and Insider Activities on REGN

Follow REGENERON PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on REGN